Literature DB >> 415836

Nephrotoxicity of cis-platinum (II) dichlorodiammine.

J J Stark, S B Howel.   

Abstract

The renal function of 15 patients receiving cis-platinum (II) dichlorodiammine (CPDD) was examined prospectively in detail to elucidate early evidence of nephrotoxicity. Patients were given a total of 49 couses of CPDD at 20 mg/m2/day for 5 days with 1,000 ml of saline prehydration. Renal function was monitored by serial determinations of serum creatinine and glomerular filtration rate (measured as 125I-iothalamate clearance) and by measurement of parameters of tubular function, including tubular reabsorption of phosphorus, urine-to-serum glucose ratio, total protein, and total free immunoglobulin light chain excretion, serum electrolytes, and urine pH and specific gravity. There was no significant change in mean serum creatinine within a course of treatment, nor was there a cumulative increase in the serum creatinine. In 9 of 19 evaluable courses there was a small transient fall in glomerular filtration rate with prompt recovery. There was no cumulative decrease in glomerular filtration rate through 3 courses of treatment. Four of the patients with preexisting renal insufficiency suffered no significant additional nephrotoxicity. There was no tubular dysfunction demonstrable in any of the patients. This study represents the first prospective detailed examination of multiple parameters of renal function in patients treated with CPDD and reveals that the only parameter to show any change with this schedule of drug administration was the glomerular filtration rate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 415836     DOI: 10.1002/cpt1978234461

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  Effect of silymarin in the prevention of Cisplatin nephrotoxicity, a clinical trial study.

Authors:  Ali Momeni; Ali Hajigholami; Shohreh Geshnizjani; Soleiman Kheiri
Journal:  J Clin Diagn Res       Date:  2015-04-01

2.  Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin.

Authors:  T J Littlewood; A P Smith
Journal:  Thorax       Date:  1984-08       Impact factor: 9.139

3.  Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).

Authors:  A W Skillen; P K Buamah; B M Cantwell; C Cornell; A W Hodson; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 4.  Developing better mouse models to study cisplatin-induced kidney injury.

Authors:  Cierra N Sharp; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

5.  Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.

Authors:  L Pendyala; S Madajewicz; S B Lele; S G Arbuck; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.

Authors:  C L Bregman; P D Williams
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 7.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

8.  Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity.

Authors:  A A Nanji; D J Stewart; N Z Mikhael
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  In the search for new anticancer drugs. VII. Platinum complexes of diaziridines and azetidine.

Authors:  G Sosnovsky; J Lukszo
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

10.  [The iodine 131-hippurate clearance for the determination of the nephrotoxic effect of cis-dichlorodiamino-platin (II) (cis-platin, cis-DDP)].

Authors:  T G Wendt; R Hartenstein; U Büll; K Schlechtweg; E A Moser
Journal:  Klin Wochenschr       Date:  1983-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.